期刊
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 58, 期 26, 页码 8752-8756出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201902612
关键词
catalase-like activity; chemoradiation therapy; controlled drug release; radiosensitizer; tumour hypoxia
资金
- National Natural Science Foundation of China [21834004, 21427807]
- International Cooperation Foundation from Ministry of Science and Technology [2016YFE0130100]
- China Postdoctoral Science Foundation [2018M640472]
- Start-up Research Grant (SRG) of University of Macau [SRG2018-00130-FHS]
- Science and Technology Development Fund of Macao SAR [FDCT 0109/2018/A3]
- Intramural Research Program (IRP) of National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH)
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [ZIAEB000073] Funding Source: NIH RePORTER
Tumor hypoxia, the Achilles' heel of current cancer therapies, is indispensable to drug resistance and poor therapeutic outcomes especially for radiotherapy. Here we propose an insitu catalytic oxygenation strategy in tumor using porphyrinic metal-organic framework (MOF)-gold nanoparticles (AuNPs) nanohybrid as a therapeutic platform to achieve O-2-evolving chemoradiotherapy. The AuNPs decorated on the surface of MOF effectively stabilize the nanocomposite and serve as radiosensitizers, whereas the MOF scaffold acts as a container to encapsulate chemotherapeutic drug doxorubicin. Invitro and invivo studies verify that the catalase-like nanohybrid significantly enhances the radiotherapy effect, alleviating tumor hypoxia and achieving synergistic anticancer efficacy. This hybrid nanomaterial remarkably suppresses the tumor growth with minimized systemic toxicity, opening new horizons for the next generation of theranostic nanomedicines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据